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Proprotein convertases are subtilisin-like serine endoproteases that cleave and hence activate a variety of proproteins, including
growth factors, receptors, metalloproteases, and extracellular matrix proteins. Therefore, it has been suggested that inhibition of
the ubiquitously expressed proprotein convertase FURIN might be a good therapeutic strategy for several tumor types. Whether
this is also the case for hepatocellular carcinoma (HCC) is currently not clear. In a mouse model for HCC expression of Furin
was not altered in the tumors, while those of PC7, PC5/6, and PACE4 significantly decreased, at least at some time points. To
investigate the impact of Furin inhibition on the development and progression of HCC in this model, Furin was genetically ablated
in the liver. Furin inactivation resulted in an increased tumor mass after 5 weeks.This was not caused by decreased apoptosis, since
no differences in the apoptosis index could be observed. However, it could at least partially be explained by increased hepatocyte
proliferation at 5 weeks.The tumors of the Furin knockoutmice were histologically similar to those in wild typemice. In conclusion,
liver-specific Furin inhibition in HCC enhances the tumor formation and will not be a good therapeutic strategy for this tumor
type.
1. Introduction
Furin is an endoprotease that belongs to the seven-member
family of subtilisin-like proprotein convertases (PCs) [1, 2].
The other family members are PC1/3, PC2, PC4, PC5/6,
PC7, and PACE4.Their physiological role is to cleave a variety
of precursor proteins (proproteins), carboxy-terminal of spe-
cific basic amino acid motifs. Cleavage is usually needed for
activation of the proteins, although exceptions exist in which
cleavage results in inactivation, modified or even opposite
activity. Precursor proteins include growth and differenti-
ation factors, receptors, adhesion molecules, and enzymes
like matrix metalloproteinases (MMPs).They play important
roles at different stages of tumor development, progression,
vascularization, andmetastasis.Therefore, it is not surprising
that the aggressiveness of tumors has been correlated with
increased PC expression, including breast, ovary, brain, skin,
prostate, and lung cancer [3–10]. In particular, the broadly
expressed PCs Furin and PACE4 have frequently been found
to be highly expressed in tumors. Nevertheless, upregulation
of the neuroendocrine specific members PC1/3 and PC2 has
also been reported in, for example, lung tumors [5, 11].
Furthermore, it has been shown that inhibition, knock-
down, and genetic ablation of Furin reduces tumorigenesis
in various human cancer cell lines [12]. For example, FURIN
inhibition in squamous cell carcinoma cell lines resulted in
a decreased proliferation, reduced anchorage-independent
growth in soft agar assays, and inhibited in vivo tumori-
genicity and invasion in nude mice [13]. In contrast, Furin
overexpression in these cell lines resulted in the opposite
phenotype and increased their proliferation and invasiveness
[14].
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Similarly, transgenic mice overexpressing Furin display
enhanced skin tumor formation [15], whereas we previously
demonstrated that genetic ablation of Furin in salivary
gland tumors reduces the tumor formation [16]. Indeed, the
development and progression of PLAG1-induced pleomor-
phic adenomas of the salivary glands was inhibited with a
simultaneous genetic ablation of Furin. The delayed tumor
onset after genetic ablation of Furin in the salivary glands
could be explained by the partially impaired processing of the
insulin-like growth factor 1 receptor (IGF1R) in the salivary
glands. In this way it interferes with IGF signaling, a major
tumorigenic pathway involved in PLAG1-induced salivary
gland tumors [17, 18].
These in vitro and in vivo lines of evidence suggest that
FURIN inhibitionmight be a possible anticancer therapy [19].
Therefore, FURIN inhibitors have been generated [20, 21].
For instance, decanoyl-Arg-Val-Lys-Arg-chloromethylketone
(decRVKR-CMK) and 𝛼1-antitrypsin Portland (𝛼1-PDX)
could decrease cell proliferation rate and invasiveness of
cancer cell lines [6, 14]. However, most FURIN inhibitors
generated so far are not specific for FURIN but also inhibit
other members of the proprotein convertases. Nevertheless,
in some cases, administration of specific FURIN inhibitors
might be required. It has been described that genetic ablation
of other proprotein convertases such as PC5/6 enhances
tumor formation [22]. For example enterocyte-restricted
ablation of PC5/6 in the APCMin /+ mouse model resulted in
a significantly higher tumor number in the small intestines,
indicating that PC5/6 protects against tumorigenesis. For
this reason specific FURIN inhibitors rather than general
proprotein convertase inhibitors may be needed to obtain
therapeutic benefit. Recently, specific FURIN inhibitors were
generated such as nanobodies against catalytically active
FURIN [23] and an engineered 𝛼1-antitrypsin variant [24].
Those inhibitors will now have to be validated on cancer cell
lines. Recently, bifunctional shRNA against Furin was used
in patients with advanced cancer in a phase 1 clinical trial of
FANG, a bi-shRNAiFurin/GMCSF DNA/Autologous tumor
vaccine [25].This treatment was safe and induced an immune
response that correlated with a longer overall survival.
With an estimated 750,000 new cases worldwide in 2008,
hepatocellular carcinoma (HCC) is the third most common
cause of cancer death [26]. Despite advances in the treatment
and early diagnosis of HCC more than 70% of HCC patients
will not benefit from the treatment because of the advanced
stage of the disease at themoment of diagnosis.Therefore, the
prognosis ofHCCpatients is generally very poorwith a 5-year
survival rate less than 5%. New therapeutic strategies to treat
this disease are thus urgently required. FURIN inhibition
might be such a possible strategy. However, so far the role
of FURIN in hepatocellular carcinoma (HCC) is not yet
clear. FURIN overexpression in HepG2 cells increased the
metastasis index and tumor size in animal models [27]. This
suggests that FURIN serves as an anticancer target in HCC.
Nevertheless, the clinical relevance of this finding was chal-
lenged since a tumor/nontumor ratio of Furin of more than
3.5 in HCC tissue predicted a better postoperative disease-
free survival in a postoperative survival analysis of HCC
patients [28]. Furthermore,Huh7 cells overexpressingFURIN
displayed a reduced tumor growth in subcutaneous xenograft
experiments, which could be reversed by administration of
synthetic FURIN inhibitors [28]. Therefore, it is still unclear
whether or not FURIN inhibition might be a good strategy
for HCC. In this study we have investigated the therapeutic
relevance of FURIN inhibition for the treatment of HCC via
genetic ablation of Furin in the liver in a mouse model for
HCC.
2. Materials and Methods
2.1. MouseModels. All animal experiments were approved by
the ethical committee of the KU Leuven and were performed
in a C57Bl/6J background.
Furfl/fl mice were generated as described previously [29].
In brief, exon 2 was flanked by loxP sites. This allowed the
conditional removal of exon 2, which contains the translation
initiation site, the signal peptide and part of the pro-domain,
leading to the inactivation of the Furin gene [29].
The ASV-B mice were used as a tumor model for HCC (a
kind gift of Dr. Evelyne Dupuy [30]). HCC was induced by
the expression of the Simian vacuolating virus 40 (SV40)-T
antigen under the control of the anti-thrombin III promoter.
The transgene was integrated on the Y-chromosome. As a
consequence male mice developed hepatic tumors, while
female mice remained tumor free.
B6⋅Cg-Tg(Alb-cre)21Mgn/J mice (The Jackson Labora-
tory stock no 003574), here abbreviated asAlb-Cremice, were
used to conditionally inactivate Furin in the liver [31]. In this
model Cre is expressed in the liver, driven by the albumin
promoter.
The ASV-B mice were intercrossed with Furfl/fl mice
for two generations to obtain ASV-B+/− Alb-Cre−/− Furfl/fl
mice. In parallel the Alb-cre mice were intercrossed with
Furfl/fl mice for two generations to obtain ASV-B−/− Alb-
Cre+/− Furfl/fl mice. Finally, ASV-B+/− Alb-Cre−/− Furfl/fl
mice were intercrossed with ASV-B−/− Alb-Cre+/− Furfl/fl
mice to obtain ASV-B+/− Alb-Cre+/− Furfl/fl (tumor bearing
male mice, in which Furin is inactivated in the liver), ASV-
B+/− Alb-Cre−/− Furfl/fl (tumor bearing male mice, in which
Furin is present in the liver), ASV-B−/− Alb-Cre+/− Furfl/fl
(female mice without tumors, in which Furin is inactivated
in the liver) and ASV-B−/− Alb-Cre−/− Furfl/fl mice (female
mice without tumors, in which Furin is present in the liver).
Those offspring mice were used for the experiments.
Mice were genotyped by PCR analysis of tail DNA using
the primes 5󸀠 GCTGTATTTATTCCGGAGAC 3󸀠 and 5󸀠
GTAGTTAGGAGCACATACTG 3󸀠 to distinguish between
Furin floxed and wild type alleles and 5󸀠 CCTGTTTTGCAC-
GTTCACCG 3󸀠 and 5󸀠 ATGCTTCTGTCCGTTTGCCG 3󸀠
to detect the presence of the Cre recombinase. Sexing of the
mice was sufficient to determine the presence of the SV40-T
transgene.
2.2. Quantitative Real-Time PCR. Total RNA was isolated
from the liver and liver tumors using the Nucleospin
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RNA midi (Macherey Nagel, Du¨ren, Germany) accord-
ing to the manufacturer’s protocol. First strand cDNA
was synthesized using iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA). Primers were designed with the
ProbeFinder software (Roche, Basel, Switzerland, listed in
Table S1 in supplementary materials available online at
http://dx.doi.org/10.1155/2015/148651). Quantitative real-time
PCR (qRT-PCR) was performed in triplicate with MyIQ Sin-
gle Color Real-Time PCR Detection System (Bio-Rad) using
SYBR Green. Samples were normalized to glyceraldehyde 3-
phosphate dehydrogenase (Gapdh). Data were analysed using
the Livak method [32].
2.3. Histological Analysis. Mouse livers were fixed in 4%
formaldehyde in PBS, embedded in paraffin and sectioned
at 5 𝜇m thickness. Sections were stained with Gill’s haema-
toxylin and eosin or with sirius red staining according to
standard procedures.
2.4. Quantification of the Proliferation and Apoptosis Index.
Ki67 staining (proliferation) and active-caspase3 staining
(apoptosis) were performed on 4 liver sections per tumor.
Those areas were randomly selected from the slides based on
the DAPI staining, to compensate for the possibly uneven
distribution of the apoptotic/proliferating cells within the
tumor mass. Rehydrated sections were heated for 20 minutes
in Target Retrieval Solution (pH 6.1, Dako). After blocking
with 20% normal goat serum (Dako) in PBS, slides were
incubated overnight at 4∘C with polyclonal rabbit anti-
Ki67 antibody (1 : 500, Abcam, ab15580) or rabbit anti-active
caspase3 antibody (1 : 400, Cell Signaling Technology, 9664S)
each diluted in Dako Antibody Diluent. As secondary anti-
body the Alexa fluor 488 goat anti-rabbit antibody was used
for 1 hour at room temperature and nuclei were stained with
DAPI (dilution 1/10000, Dako). Images were taken using the
Leica DMRB Fluorescence microscope. Ki67, active caspase 3
and DAPI positive cells were counted using the cell counter
plugin of the Image J software (National Institute of Health
(NIH), Bethesda, USA). At least 2000 cells were counted per
liver. The proliferation and apoptosis index was calculated by
counting the number of Ki67 or active caspase 3 positive cells,
respectively, divided by the number of DAPI positive nuclei
(total number of cells).
2.5. Western Blot Analysis. Livers and liver tumors were
dissected and snap frozen in liquid nitrogen. Snap frozen
tissues were homogenized in Cell Lysis Buffer (Cell Signaling
Technology) supplementedwith complete protease inhibitors
(Roche). Expression of AFP was analyzed by western blot
analysis using standard procedures. Rabbit anti-AFP (1/1000,
Abcam) and rabbit anti alpha-actin (1/1000) diluted in PBS
with 0.5% (w/v) nonfat dry milk and 0.2% (v/v) Triton
X100 were used as primary antibodies. Detection of proteins
was carried out with the ECL method using the Western
Lightning enhanced luminol-based chemiluminescenceHRP
substrate (Perkin Elmer).
2.6. Statistical Analysis. Data are represented as mean ± SEM
and significance is shown on graphs as𝑃 < 0.05∗,𝑃 < 0.01∗∗,
or 𝑃 < 0.001∗∗∗. Student’s t-tests or two-way ANOVA tests
were used as indicated in the figure legends.
3. Results
3.1. Expression Levels of the Constitutively Secreted PCs in
Liver Tumors of ASV-B Mice. In this study, the role of the
PCs and more specifically the role of Furin were investigated
in a mouse model for HCC. Therefore, the ASV-B mice
were used as a well-characterized tumor model for HCC
[30]. These mice express the SV40 large T antigen under
the control of the anti-thrombin III promoter and mimic the
progression of humanHCC. Like in humans, thesemice show
an age dependent progression from hyperplasia/dysplasia
(4–8 weeks) to nodular adenoma (12 weeks) and finally
carcinoma (>16 weeks). In the studies presented here, 5-, 13-,
and 19-week-oldmicewere investigated, corresponding to the
different stages of the tumor progression.
Since it has been described that proprotein convertases
are often differentially expressed in tumors, the expression
levels of the constitutively secreted proprotein convertases
(Furin, PC5/6, PC7, and PACE4) were analyzed in the liver
tumors of ASV-B mice. The expression levels of Furin in
ASVB+/− Alb-Cre−/− Furfl/fl mice did not change signifi-
cantly in the liver tumors compared to those in normal livers
at every time point investigated (Figure 1(a)). In contrast,
the expression of PC7 was significantly reduced in the liver
tumors of 5-week-old mice (Figure 1(b)), the expression of
PC5/6 was significantly reduced in the liver tumors of 5-
week-old and 13-week-old mice (Figure 1(c)), and the expres-
sion levels of PACE4 were significantly reduced in the liver
tumors at all time points investigated (Figure 1(d)).
3.2. Conditional Inactivation of Furin in the Liver of ASV-
B Mice Resulted in an Early Tumor Onset. To explore the
in vivo role of Furin in hepatocellular carcinoma, the Furin
gene was inactivated in the hepatocytes of ASV-B mice using
the Cre/LoxP system. Furin was genetically ablated in the
HCC tumors and in the livers of littermate control mice via
intercrossing with Alb-Cre mice as described in materials
and methods. This resulted in a nearly complete ablation
of Furin expression (>95%) in the livers of the Furin KO
mice with and without the tumors as shown by qRT-PCR
at the different time points investigated (Figure 1(a)). No
compensatory upregulation was observed for any of the PCs
in Furin knockout tissue (Figure 1). Furin inactivation had a
significant impact on the tumorigenic process. Already after
5 weeks, the ratio of the tumor weight relative to the total
body weight was significantly increased by 27% in the Furin
KO as compared to Furin wild type mice (Figure 2(a)). No
significant differences in total body weight were observed
between genotypes. In the ASV-B mouse model, the SV40
large T-antigen is expressed in all hepatocytes. This leads
to hyperplasia and tumor formation in the whole liver.
In contrast to human HCC, the tumor mass is thus not
surrounded by normal liver. Photographs of the liver tumors
of 19-week-old animals are provided in Figures 2(b) and 2(c).
Upon histological analysis of the tumors, no differences could
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Figure 1: Expression levels of the constitutively secreted proprotein convertases in the livers and liver tumors. (a)The expression levels ofFurin
in Furin wild type mice did not change significantly in the liver tumors compared to those in normal livers at every time point investigated.
(b) Expression of PC7 was significantly reduced in the liver tumors of 5-week-old mice, but not at later time points. (c) The expression of
PC5/6was significantly reduced in the liver tumors of 5-week-old and 13-week-oldmice. (d)The expression levels of PACE4were significantly
reduced in the tumors at all time points investigated. (a) Furin expression was nearly completely ablated in the livers of the Furin KO mice
with and without the tumors as shown by qRT-PCR at the different time points investigated. (b, c, d) Furin inactivation in the liver and liver
tumors did not significantly alter the expression levels of other PCs. Two-way ANOVA was used to determine statistical significance. Data
are shown as fold induction ± SEM relative to ASVB−/− Alb-Cre−/− Furfl/fl mice (𝑛 = 3–11).
be observed between the tumors for Furinwild typemice and
Furin knockout mice (data not shown).
3.3. The Enlarged Tumor Mass after Genetic Ablation of
Furin Is Caused by an Increased Proliferation. The increased
tumor mass after genetic ablation of Furin in the liver
could be explained by a decreased apoptosis and/or an
increased proliferation of the hepatocytes. The apoptosis
indexwas determined at the different time points investigated
as described in Materials and Methods. The apoptosis index
in the liver tumors of Furin knockout mice was similar to
that of wild type littermates at every time point investigated
(Figure 3(a)). However, the hepatocyte proliferation index
was significantly increased in the liver tumors of 5-week-
old Furin knockout mice as compared to those in the liver
tumors of littermate Furin wild type mice (Figure 3(b)).
This difference was not observed in older mice. Therefore,
increased proliferation is at least one of the mechanisms that
can explain the early tumor onset after genetic ablation of
Furin in the liver tumors.
3.4. HCC Biomarkers were Expressed at Similar Levels in Furin
Wild Type and Conditional Furin Knockout Mice. We subse-
quently analyzed the expression pattern of two biomarkers
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Figure 2: Conditional inactivation of Furin in the livers of ASV-B mice resulted in an increased tumor mass. (a) Conditional inactivation of
Furin in the livers of ASV-Bmice had a significant impact on the tumorigenic process. Already after 5 weeks the ratio of the tumor weight and
the total body weight was significantly increased (27%) in the Furin KO mice. Student’s t-test was used to determine statistical significance
(𝑛 = 3–14). (b) A representative photograph of 19-week-old ASVB+/− Alb-Cre−/− Furfl/fl mice. (c) A representative photograph of 19-week-old
ASVB+/− Alb-Cre+/− Furfl/fl mice.
which are frequently used to detect HCC in humans, in
the liver. The ASV-B transgene significantly upregulated
Glypican 3 (Gpc3) (5 weeks: 𝑃 = 0.000203, 13 weeks: 𝑃 =
0.000002, 19 weeks: 𝑃 < 0.000001) and alpha-fetoprotein
(Afp) (5 weeks: 𝑃 = 0.001136, 13 weeks: 𝑃 = 0.001454, 19
weeks: 𝑃 = 0.000001) expression (Figure 4). Therefore, the
expression levels of these genes were significantly increased
in the liver tumors as compared to those in normal livers
as demonstrated by qRT-PCR. Nevertheless, there was no
significant effect of the Furin inactivation on the expression
levels ofGpc3 (5weeks:𝑃 = 0.72, 13weeks:𝑃 = 0.29, 19weeks:
𝑃 = 0.81) and Afp (5 weeks: 𝑃 = 0.12, 13 weeks: 𝑃 = 0.61, 19
weeks: 𝑃 = 0.11) in the liver tumors by qRT-PCR. Likewise,
also at the protein level the expression of AFP increased in
the tumors of 13- and 19-week-old mice and the expression of
AFP was similar in tumors of Furin knockout and Furin wild
type mice (Figure 5).
4. Discussion
FURIN inhibition has been proposed as a therapeutic strategy
for several tumor types [4, 14, 16]. However, so far few studies
reported about the role of Furin in HCC [27, 28]. Here we
show in an in vivo model for HCC that genetic ablation
of Furin does not provide therapeutic benefit. In contrast,
we observed enhanced early-onset tumor development. The
ASV-B transgenic mouse model used here to investigate the
role of Furin in HCC [30] mimics human HCC quite well
[30]. Like in human HCC, the tumor progresses from a
hyperplasia/dysplasia stage to a nodular adenoma and finally
6 BioMed Research International
ASVB+/−Alb-Cre−/− Furfl/fl
ASVB+/−Alb-Cre+/− Furfl/fl
Age (weeks)
10
8
6
4
2
0
5 10 15 20
Ap
op
to
sis
 in
de
x 
(%
)
(a)
ASVB+/−Alb-Cre−/− Furfl/fl
ASVB+/−Alb-Cre+/− Furfl/fl
∗
Age (weeks)
5 10 15 20
100
80
60
40
20
0
Pr
ol
ife
ra
tio
n 
in
de
x 
(%
)
(b)
Figure 3:The increased tumor mass after genetic ablation of Furin in the liver can be explained by a decreased apoptosis and/or an increased
proliferation of the hepatocytes. (a)The apoptosis index in the liver tumors of Furin knockout mice was similar to that of wild type littermates
at every time point investigated. (b) The hepatocyte proliferation index was significantly increased in the liver tumors of 5-week-old Furin
knockout mice as compared to those in the liver tumors of littermate Furin wild type mice. This difference could not be observed in older
mice. Increased proliferation is thus at least one of the mechanisms that can explain the increased tumor mass after genetic ablation of Furin
in the liver tumors. Student’s t-test was used to determine statistical significance (𝑛 = 3-4).
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Figure 4: Expression of biomarkers for humanHCC is not altered upon genetic ablation of Furin in the liver.The expression levels ofGlypican
3 (Gpc3) (a) and alpha-fetoprotein (Afp) (b) were significantly increased in the liver tumors compared to those in normal livers at every time
point investigated as assessed by qRT-PCR. However, the expression levels of Gpc3 and Afp were similar in tumors of Furin knockout and
Furin wild type mice as assessed by qRT-PCR. Two-way ANOVA was used to determine statistical significance. Data are represented as fold
induction ± SEM relative to ASVB−/− Alb-Cre−/− Furfl/fl mice (𝑛 = 3–5).
a carcinoma stage. We demonstrated that the expression
of several biomarkers used to detect HCC in humans,
such as Gpc3 and Afp, is also upregulated in this tumor
model, providing evidence at the molecular level that the
tumorigenic process resembles human HCC. Despite the
similarities with the human tumors, there are also some
differences. The SV40 large T antigen is expressed under
the control of the anti-thrombin III promoter in almost all
hepatocytes, leading to severe hyperplasia of the liver tissue
and finally a huge multifocal tumor mass (up to almost
40% of the total body weight), which is not surrounded
by normal liver tissue. In contrast, in humans the tumor
arises from a single or few progenitor cells and is surrounded
by normal liver tissue. Nevertheless, given the histological
and molecular similarities with human HCC, this model is
suitable to investigate the role of Furin in HCC development
BioMed Research International 7
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Figure 5: Expression of AFP is not altered upon genetic ablation of Furin in the liver.The expression of AFP was increased in the liver tumors
of 13- and 19-week-old mice compared to that in normal livers as assessed by western blot analysis. However, the expression of AFP was
similar in tumors of Furin knockout and Furin wild type mice.
and progression. Therefore, Furin was genetically ablated in
the hepatocytes of the ASV-Bmice.This resulted in increased
hepatocyte proliferation and increased tumor mass already
at 5 weeks. This is in agreement with data obtained from
HCC patients where Furin overexpression predicts a better
postoperative disease-free survival and suggests that Furin
inhibition in the liver will not be a good therapeutic strategy
for liver cancer [28]. Thus, depending on the tumor type,
Furin inhibition might be advantageous as an anticancer
strategy, such as in pleomorphic adenomas of the salivary
glands, or disadvantageous. These tumor type dependent
differences in the impact of Furin ablation on the tumorigenic
process could be explained by different molecular mecha-
nisms underlying the tumor formation. For example, one of
the major signaling pathways involved in the tumorigenic
process of PLAG1-induced pleomorphic adenomas of the
salivary gland is the IGF signaling pathway. Indeed, Igf2 isa
direct target gene of the transcription factor PLAG1 [33],
which plays an important role in the tumorigenic process,
since genetic ablation of Igf2 in the PLAG1 transgenic mouse
model significantly delayed the tumor formation [18]. We
previously demonstrated that genetic ablation of Furin in
salivary gland tumors interfered with IGF signaling since
it resulted in an impaired processing of the IGF1R [16].
This might, at least in part, explain the delay in the tumor
formation upon Furin inactivation in this tumor type. Given
the wide range of substrates of FURIN, the overall result
is probably a compound phenotype caused by complete or
partial inhibition of cleavage of a number of substrates.
In contrast, in the ASV-B mice, the transforming activity
of the SV40 large T antigen is largely due to its inactivation
of the retinoblastoma proteins, which induces cell cycle entry
and blocks the p53 tumor suppressor [34]. So far no FURIN
substrates have been identified downstream of this signaling
cascade. Nevertheless, the lack of Furin in hepatocytes in
this mouse model enhances the HCC tumorigenic process.
However, the FURIN substrate(s) leading to the early tumor
onset is currently unknown and will be part of further
investigations.
5. Conclusions
It has previously been shown that FURIN inhibition reduces
tumorigenesis in various human cancer cells, suggesting that
Furin inhibition might be a good therapeutic strategy for
cancer [12]. However, here we demonstrate that the impact
of Furin inactivation on the tumorigenic process depends on
the tumor type. Furin inhibition in a mouse model for HCC
leads to early tumor onset with significantly larger tumors
due to increased hepatocyte proliferation. Therefore, Furin
inhibition will not be a good therapeutic strategy for HCC
and might even enhance tumor formation.
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